Sichuan Kelun-Biotech Biopharmaceutical (6990) 44th Annual J.P. Morgan Healthcare Conference summary

Company overview and R&D focus

• Specializes in novel drug development for oncology, immunology, metabolism, and other diseases, leveraging a differentiated OptiDC drug-conjugate platform.

• Operates over 30 pipeline programs, with four approved products and two at NDA stage, and expects further approvals and label expansions in 2026.

• Employs around 2,000 staff, with significant investment in R&D, manufacturing, and commercialization.

Product pipeline and clinical progress

• Four products approved in China, including TROP2 ADC (sac-TMT) and HER2-ADC, with multiple indications in breast, lung, and GI cancers.

• Nine novel drug conjugates in clinical stage, including bispecific and radioisotope ADCs, targeting major oncology indications.

• Five pivotal clinical studies for breast cancer, six for lung cancer, and one for GI cancer underway; several Phase 1/2 programs expected to advance.

• Clinical data from six pivotal studies and multiple early-phase studies presented at major conferences and published in top journals.

Commercialization and partnerships

• Three core products included in China's National Reimbursement Drug List (NRDL 2025), effective this month.

• Strategic collaborations with MSD, Ellipses, Windward Bio, and Crescent Biopharma to expand global reach and pipeline value.

• MSD is a major shareholder and partner, with 16 global Phase 3 studies ongoing for sac-TMT in various cancers.

• Commercial team established with access to major hospitals and key opinion leaders, with plans for further expansion.